Summary

• Eli Lilly and Company ends the first half of 2026 on a high note.
• Today, LLY stock reached a 52-week high of $1,207.59.
• Key drivers behind Eli Lilly's recent rally are the unprecedented efficacy of retatrutide in treating people with severe obesity, as well as the strong performance of Mounjaro and Kisunla.
• So, in the first quarter, LLY sales of Kisunla, its Alzheimer's medication, were $124 million, up 490.5% year-over-year.
• However, due to sluggish demand for Omvoh, coupled with LLY stock trading at a non-GAAP P/E ratio [FWD] of 31.1x, I'm downgrading its rating to Hold.

Eli Lilly and Company (LLY), my favorite in the $190 billion GLP-1 drugs market, after a small pullback, is again trading above the +2σ band formed from the VWAP.

And before I discuss Eli

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.